Rivas-Vazquez R A, Carrazana E J, Rey G J, Blais M A, Racher D A
Neurologic Center of South Florida, FL, United States of America.
Clin Neuropsychol. 2000 Feb;14(1):93-109. doi: 10.1076/1385-4046(200002)14:1;1-8;FT093.
The expected rise in prevalence rates of Alzheimer's disease over the next several decades has generated a great deal of attention at all levels of society, including governmental and scientific communities. These concerns have resulted in a vast number of research studies which have yielded medications focusing primarily on the symptomatic relief of the cognitive, neuropsychiatric and behavioral alterations felt to be pathognomic of the disease. Medical and pharmacological interventions which impact the onset or delay the progression of the illness are not yet readily available. We review and discuss the medications which are currently used for the symptomatic treatment and management of the disease, as well as discuss new pharmacological strategies which are under investigation and development.
预计在未来几十年里，阿尔茨海默病的患病率将会上升，这一情况已在社会各层面引发了广泛关注，其中包括政府部门和科学界。这些担忧促使大量研究展开，从而研发出了一些药物，这些药物主要致力于缓解被认为是该疾病特征性表现的认知、神经精神及行为改变的症状。目前，能够影响疾病发作或延缓其进展的医学和药物干预手段尚不可用。我们将对目前用于该疾病症状治疗和管理的药物进行综述和讨论，并探讨正在研究和开发的新药物策略。
